Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. The trade was a 12.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Henry Schein Price Performance
Shares of HSIC opened at $73.91 on Friday. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The stock has a market cap of $9.21 billion, a P/E ratio of 30.41, a price-to-earnings-growth ratio of 2.15 and a beta of 0.87. The stock’s 50-day moving average price is $70.68 and its two-hundred day moving average price is $69.69. Henry Schein, Inc. has a 1 year low of $63.67 and a 1 year high of $82.63.
Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s revenue for the quarter was up .4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 earnings per share. On average, equities analysts predict that Henry Schein, Inc. will post 4.78 earnings per share for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of analysts have issued reports on HSIC shares. JPMorgan Chase & Co. lowered their target price on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Barrington Research reaffirmed an “outperform” rating and issued a $82.00 price target on shares of Henry Schein in a research note on Wednesday, November 6th. Evercore ISI increased their target price on shares of Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 8th. UBS Group reduced their price target on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Finally, Robert W. Baird cut their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $78.89.
Check Out Our Latest Research Report on Henry Schein
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Articles
- Five stocks we like better than Henry Schein
- Using the MarketBeat Dividend Tax Calculator
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- The Basics of Support and Resistance
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- Technology Stocks Explained: Here’s What to Know About Tech
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.